Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2025-07-29

FDA Approved: ADALIMUMAB — Supplemental Application (Sandoz Inc)

View source ↗

Summary

FDA approved a supplemental application for Sandoz Inc for the adalimumab biosimilar ADALIMUMAB-ADAZ, enabling its use with indications consistent with the refe…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • ADALIMUMAB-ADAZ (adalimumab)

Snippet

SUPPL AP for ADALIMUMAB (ADALIMUMAB-ADAZ)